Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2022-07-20
2022-09-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pain and Trismus Control in Third Molar Surgery: Ibuprofen, Ketamine, and Their Combination
NCT05923775
Is Therapeutic Elastic Bandage As Effective As Corticosteroids Following Third Molar Surgery?
NCT04200885
Etodalac, Etoricoxib and Dexamethasone for Prevention of Pain ,Swelling and Trismus Following Third Molar Surgery
NCT00793052
A COMPARISON OF TRANSDERMAL DICLOFENAC AND ORAL COMBINATION OF PARACETAMOL AND IBUPROFEN IN POSTOPERATIVE PAIN MANAGEMENT FOLLOWING SURGICAL EXTRACTION OF MANDIBULAR THIRD MOLAR- A RANDOMISD CONTROLLED TRIALS.
NCT06146491
Perineural and Systemic Dexamethasone Use in Dental Surgeries in Terms of Anesthesia Duration and Postop Complaints
NCT06318013
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lornoxicam
Lornoxicam, 8 mg twice per day for four days
Lornoxicam 8 Mg Oral Tablet
Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
Etodolac
Etodolac, 400 mg tid per a day for four days
Lornoxicam 8 Mg Oral Tablet
Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lornoxicam 8 Mg Oral Tablet
Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Asymptomatic Third Molar (No history of infection)
* Systemically Healthy Person
* Person Between aged 18-30
Exclusion Criteria
* People who had any systemic disease
* People who are gastrointestinal problems
* People who are sensitive to drugs used in study
* Lower Third Molar associated with cysts and infections
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kutahya Health Sciences University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zulfikar Karabiyik
Research Assistant
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zülfikar Karabıyık
Kütahya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.